Description

The recombinant human IL-15 fusion protein is a genetically engineered chimeric immunomodulatory molecule constructed by tandem fusion of the IL-15 cytokine core, sushi domain of IL-15 receptor α (IL-15Rα), and human IgG Fc fragment through flexible linkers.

This molecular design mimics the natural trans-presentation mechanism of IL-15, where the sushi domain mediates high-affinity binding to IL-15Rα to form stable superagonist complexes, while the Fc fragment enhances molecular stability, prolongs serum half-life, and achieves extended pharmacokinetic properties through FcRn-mediated recycling.

In the field of cell therapy, this fusion protein significantly enhances the expansion efficiency and viability of immune cells during in vitro culture processes, particularly in preparing highly active NK cell and tumor-specific T cell therapeutic products.

By persistently activating the IL-2/IL-15 receptor βγ complex (CD122/γc), it effectively promotes the proliferation and functional maintenance of CD8+ memory T cells, NK cells, and NKT cells, while preserving the metabolic fitness and anti-tumor phenotype of effector cells.

This innovative structural design overcomes the limitations of natural IL-15 such as short half-life and low bioavailability, providing an optimized molecular tool for cancer immunotherapy and the development of cell therapy products.

Specifications

Cytokines Details
Synonyms	Interleukin-15
Accession	UniProt P40933 & Q13261
Expressed Region	P40933 (Asn23–Ser136 [Asn72Asp]) & Q13261 (Ile31–Arg95)
Fusion Tag	Human IgG1 Fc fragment fused to the C-terminus
Expression System	HEK293 cells
Predicted Molecular Weight	53.5 kDa
Purity	> 95% as determined by SDS-PAGE and HPLC
Endotoxin	< 0.01 EU per 1 μg of protein (LAL method)
Biological Activity	Measured by CTLL-2 cell proliferation assay with an ED₅₀ of 0.2–3 ng/mL, corresponding to a specific activity > 5.0 × 10⁶ IU/mg
Formulation	Lyophilized from sterile 20 mM phosphate-buffered saline (PBS), pH 7.4, typically containing 6–8% (w/v) mannitol as a stabilizing protectant

Features

✔ IL-15 Superagonist Design
Sushi domain–mediated trans-presentation enables sustained and potent IL-15 signaling.
✔ Fc-Fusion Extended Stability
Human IgG1 Fc enhances molecular stability and functional persistence via FcRn recycling.
✔ High Biological Activity
Demonstrates strong CTLL-2 proliferation activity with low ED₅₀ and reliable cytokine potency.
✔ DMF Filed (038127)
Supports regulatory readiness for GMP cell and gene therapy manufacturing.

Applications

NK Cell Expansion and Activation

Drives robust NK cell proliferation while preserving cytotoxic and anti-tumor function.

CD8⁺ Memory T Cell Maintenance

Sustains long-term survival and functional fitness of tumor-specific T cells.

Cell Therapy Manufacturing

Optimized cytokine supplement for NK- and T-cell–based CGT workflows.

Cancer Immunotherapy Research

Enables development of next-generation immune effector cell products.

Stability & Storage

Lyophilized powder: Stable for 12 months at -80°C or 6 months at -20°C when stored inthe original sealed container under desiccant.
Reconstitution: Dissolve in sterile Water for Injection, 0.9% NaCl, or PBS (pH 7.4)maintaining final concentration ≥100 µg/mL to prevent adsorption.
Handling: Aliquot to avoid repeated freeze-thaw cycles.

Cautions

• Research Use Only: This product is not intended for diagnostic or therapeutic use.

• Handling: Follow recommended storage and handling instructions to maintain product stability.

• Support: Contact technical support if assistance is required.

Documents

📄 GMP-TL202 Data Sheet 📄 GMP-TL202 SDS 📄 GMP-TL202-0050 COA 📄 GMP-TL202-0100 COA

Recombinant Human IL-15 Protein